Insider Selling: Natera Inc (NTRA) Insider Sells $3,443,340.22 in Stock

Natera Inc (NASDAQ:NTRA) insider Jonathan Sheena sold 166,667 shares of the business’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $20.66, for a total value of $3,443,340.22. Following the sale, the insider now owns 372,583 shares of the company’s stock, valued at approximately $7,697,564.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Sheena also recently made the following trade(s):

  • On Monday, September 24th, Jonathan Sheena sold 324 shares of Natera stock. The shares were sold at an average price of $23.78, for a total value of $7,704.72.
  • On Friday, September 14th, Jonathan Sheena sold 166,667 shares of Natera stock. The shares were sold at an average price of $24.27, for a total value of $4,045,008.09.

Shares of NASDAQ:NTRA opened at $21.36 on Friday. The company has a market cap of $1.30 billion, a P/E ratio of -8.90 and a beta of 2.24. The company has a debt-to-equity ratio of -3.32, a quick ratio of 1.56 and a current ratio of 1.69. Natera Inc has a 12-month low of $8.60 and a 12-month high of $29.62.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.55). The company had revenue of $63.07 million for the quarter, compared to analysts’ expectations of $61.71 million. Natera had a negative return on equity of 752.93% and a negative net margin of 59.07%. Natera’s quarterly revenue was up 20.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.55) earnings per share. As a group, research analysts predict that Natera Inc will post -2.02 earnings per share for the current fiscal year.

NTRA has been the subject of several recent research reports. Morgan Stanley boosted their price objective on Natera from $21.00 to $41.00 and gave the company an “overweight” rating in a report on Friday, September 28th. Canaccord Genuity boosted their price objective on Natera from $25.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 16th. TheStreet upgraded Natera from a “d” rating to a “c-” rating in a report on Thursday, August 9th. Craig Hallum boosted their price objective on Natera from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Finally, Zacks Investment Research downgraded Natera from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Natera presently has an average rating of “Buy” and a consensus target price of $26.00.

Large investors have recently made changes to their positions in the stock. State Board of Administration of Florida Retirement System purchased a new position in shares of Natera during the second quarter valued at approximately $200,000. Paradigm Capital Management Inc. NY purchased a new position in shares of Natera during the second quarter valued at approximately $207,000. Cubist Systematic Strategies LLC purchased a new position in shares of Natera during the second quarter valued at approximately $252,000. Woodmont Investment Counsel LLC purchased a new position in shares of Natera during the second quarter valued at approximately $258,000. Finally, Jane Street Group LLC purchased a new position in shares of Natera during the second quarter valued at approximately $313,000. 66.31% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Further Reading: What is the yield curve?

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply